Bart De Leeuw
Partner
Works at Fund+
Investor profile | Builders Republic
About
Partner at Fund+ in Belgium, Bart De Leeuw invests from Seed to Series B with check sizes of €5 to €15 million, focusing on a specialized thesis in biotech and life sciences. His portfolio includes Coave Therapeutics, EyeD Pharma, and EPICS Therapeutics, where he serves on the board. His background reflects a strong finance profile: 14 years at Ernst & Young in IFRS, followed by financial roles at Ackermans & van Haaren and as CFO of Fortino Capital Partners, before moving into operations as CEO of WOLLUX.
Profile
- Role
- Partner
- Fund
- Fund+
- Nationality
- Belgian